Title:IL-6, IL-1β, and MDA Correlate with Thrombolysis in Myocardial Infarction
(TIMI) Risk Score in Patients with Acute Coronary Syndrome
Volume: 15
Issue: 2
Author(s): Marcus V. de Paula da Silva, Pedro Henrique Villar-Delfino, José A. Nogueira-Machado and Caroline M.O. Volpe*
Affiliation:
- Faculdade Santa Casa BH, Programa de Pós-Graduação em Medicina-Biomedicina, Hospital Santa Casa de Belo
Horizonte, Minas Gerais, Brazil
Keywords:
Acute coronary syndrome, TIMI, IL-6, IL-1β, MDA, inflammation.
Abstract:
Background: Inflammation plays a significant role in the pathophysiology of Acute
Coronary Syndrome (ACS) but is not included in current risk stratification.
Objective: This study aimed at determining the association between Thrombolysis in Myocardial
Infarction (TIMI) risk score and inflammatory biomarkers in the ACS, including unstable angina
(UA), Non-ST Segment Elevation Myocardial Infarction (NSTEMI), and ST-segment elevation myocardial
infarction (STEMI). We hypothesized that inflammatory biomarkers could add prognostic
value to the TIMI risk score.
Methods: In this cross-sectional study, serum levels of interleukins (IL)-6 and IL-1β and MDA
(malondialdehyde) were quantified by ELISA and colorimetry, respectively, of patients with ACS
(n = 48; 31.3 % with UA, 33.3 % with NSTEMI, and 35.4 % with STEMI) and healthy controls (n
= 43). We assessed the TIMI scores in the first 24 h after symptom onset.
Results: The results showed that patients with ACS had significantly higher levels (p<0.05) of the
inflammatory biomarkers IL-6, IL-1β, and MDA than the control group. However, we found no significant
differences in IL-6, IL-1β, and MDA levels among the patients with ACS according to
their classification as UA, NSTEMI, and STEMI. Positive correlations were observed between TIMI
and IL-6 (r=0.68), IL-1β (r= 0.53), and MDA (r=0.58) in patients with UA and between TIMI
and IL-1β (r= 0.62) in STEMI patients.
Conclusion: These data suggested the presence of a pro-inflammatory profile in patients with ACS
as well as positive correlations between TIMI scores and the inflammatory biomarkers IL-6, IL-1β,
and MDA in patients with UA and between TIMI scores and IL-1β in patients with STEMI. Combining
inflammatory biomarkers with the TIMI risk score could provide better insight into the processes
involved in ACS.
